Over the past year, since the national launch of Pharmacy First in 2024, community pharmacies have quietly stepped into a much bigger role in frontline healthcare. For many people, this has already meant quicker access to treatment for minor illnesses. But what we’re seeing now is only the beginning — and the next stage is even more significant.

Having spent a working lifetime in general practice, I’ve watched this shift with real interest. It’s easy to assume it’s just a cost‑cutting exercise or a way to push patients away from GPs. In truth, it’s a carefully planned evolution of primary care. And for once, it feels like the NHS is moving in a direction that genuinely benefits patients, pharmacists and GPs alike.

The Present: Pharmacy First and the Seven Pathways

The Pharmacy First service, launched nationally in 2024, allows community pharmacists to assess and treat seven common conditions:

• Sinusitis
• Sore throat
• Ear infections
• Infected insect bites
• Shingles
• Impetigo
• UTIs in women

Pharmacists can supply treatment — including antibiotics — under strict NHS protocols. Every consultation is automatically sent to the patient’s GP, so continuity of care is preserved.

The payment model is deliberately designed to avoid overprescribing:

• £15 per consultation
• £1,000 monthly service fee
• £2 supply fee

Pharmacies are paid for the consultation, not for the medicines they supply. They still reclaim the cost of any treatment issued, but there is no extra fee per item — and they receive the consultation fee even if no medicine is supplied. This removes any financial incentive to prescribe unnecessarily.

The Future: Independent Prescribing (2026 and Beyond)

The real transformation arrives later in 2026, when all newly qualified pharmacists will register as Independent Prescribers (IPs). This is one of the most significant changes to primary care in decades — and it’s backed by major investment.

In May 2026, the Department of Health and Social Care announced a £340 million expansion of community pharmacy prescribing, confirming that independent prescribing will become a mainstream NHS service from autumn 2026. It’s a clear signal of intent: pharmacies are being positioned as a core part of the clinical workforce.

What Independent Prescribers Will Be Able to Do

IP‑qualified pharmacists will be able to:

• Diagnose and prescribe for a much wider range of conditions
• Manage aspects of long‑term conditions such as hypertension, asthma and thyroid disease
• Issue NHS prescriptions through the Electronic Prescription Service
• Provide treatment without needing a GP referral

In practice, they will be able to prescribe almost anything a GP can — with a few exceptions such as certain controlled drugs and specialist‑only medicines.

This does not replace GPs. Instead, it frees them to focus on complex, frail and multi‑morbid patients, where their expertise is most needed.

What About Existing Pharmacists?

A common question — and an understandable one — is what happens to the thousands of pharmacists already working in community settings.

The answer is reassuring: they can absolutely take part, and many already are.

1. Pharmacists who already hold the qualification

A growing number already have Independent Prescribing status, particularly those who have worked in GP practices, PCNs or hospitals. They will be the early adopters of the new services.

2. Pharmacists who want to train

Most community pharmacists fall into this group. They can complete NHS‑funded training through accredited universities, followed by supervised practice with a Designated Prescribing Practitioner (DPP). Training typically takes 6–12 months, and thousands of places have been funded to prepare the workforce.

3. Pharmacists who choose not to train

They can still deliver Pharmacy First, vaccinations and PGD‑based services — but they will not be able to run the new prescribing‑based clinics.

NHS England’s aim is for most pharmacies to have at least one Independent Prescriber by 2027–28.

Safeguards: Preventing Overprescribing and Protecting Patients

Concerns about overprescribing are understandable — but the safeguards are robust and multi‑layered:

• IPs can only prescribe within their competence
• All prescriptions appear in the GP record automatically
• NHS prescribing analytics flag unusual patterns
• The GPhC regulates and audits prescribing practice
• Payment is not linked to the number of medicines supplied

In reality, pharmacists tend to be cautious prescribers. They know they are personally accountable for every decision.

What This Means for Patients

For most people, these changes will feel like a welcome improvement:

• Faster access to treatment
• Fewer delays waiting for GP appointments
• More convenient care close to home
• A joined‑up record shared with the GP

It’s care that feels closer, quicker and more responsive — exactly what patients have been asking for.

What This Means for General Practice

From my own experience, GP workload has been stretched for years. Many appointments are taken up by minor illnesses that could be safely managed elsewhere.

Pharmacy First — and especially Independent Prescribing — will help rebalance the system. GPs will still oversee complex care, chronic disease management, safeguarding and diagnostics. But they will no longer be the default first stop for every minor ailment.

This is not a loss of control. It is a redistribution of work to the right professional at the right time — something general practice has needed for a long time.

A Thoughtful Step Forward

These changes are not perfect, and they will take time to settle. But the direction of travel is clear: pharmacies are becoming an essential part of the NHS’s frontline clinical workforce.

However, for these changes to succeed, the public will need to understand and trust them. Without a clear national awareness campaign, the shift may be harder to implement. People need reassurance that this is not about cutting corners or reducing access to GPs, but about expanding the range of professionals who can safely help them. If the public can see that these developments are positive — and designed for everyone’s benefit — then the transition will be far smoother.

• For patients, it means quicker care.
• For GPs, it means more time for those who truly need them.
• For pharmacists, it is long‑overdue recognition of their clinical training.
• For the NHS, it is a pragmatic evolution that reflects the realities of modern healthcare.

As someone who has seen the pressures on primary care first‑hand, I see this as a positive, sensible and overdue step forward.

References (Including 2026 Sources)

Department of Health and Social Care & NHS England (2026). £340 million pharmacy boost brings faster care to the high street. NHS Business Services Authority (2026). Community Pharmacy Independent Prescribing Pathfinder Programme. The Pharmaceutical Journal (2026). NHS‑funded community independent prescribing announced as part of the 2026/27 contract. NHS England (2024). Pharmacy First: Service Specification. NHS England (2023). Primary Care Recovery Plan. General Pharmaceutical Council (2024). Standards for Prescribing. Health Education England (2022). Initial Education and Training Standards for Pharmacists.